⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662697 | 0.72 | — | — | |
| SCHEMBL1727812 | 0.72 | — | — | |
| SCHEMBL1727810 | 0.72 | — | — | |
| SCHEMBL27678809 | 0.67 | — | — | |
| SCHEMBL31316927 | 0.64 | — | — | |
| SCHEMBL16588890 | 0.64 | — | — | |
| SCHEMBL5049805 | 0.62 | — | — | |
| SCHEMBL917244 | 0.62 | CYP19A1 (0.41) | — | |
| SCHEMBL3429163 | 0.61 | FOLH1 (0.33) | — | |
| SCHEMBL60018 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119592953-A | Etching liquid composition | 东进世美肯株式会社 | 2025-03-11 | — | — | CN | claimed |
| CN-112385019-A | Etchant composition | 朗姆研究公司 | 2021-02-19 | — | — | CN | claimed |
| CN-119592953-A | Etching liquid composition | 东进世美肯株式会社 | 2025-03-11 | — | — | CN | disclosed |
| US-11345852-B2 | Etchant composition | LAM RESEARCH CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210277308-A1 | ETCHANT COMPOSITION | LAM RESEARCH AG (AT) | 2021-09-09 | — | — | US | disclosed |
| CN-112385019-A | Etchant composition | 朗姆研究公司 | 2021-02-19 | — | — | CN | disclosed |
| US-8003643-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100075970-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-7655649-B2 | Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties | MERCK SHARP & DOHME CORP. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1737843-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| EP-1737843-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100344-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |